Interpretation of the latest policy on inclusion of repotinib in medical insurance in 2025

Repotrectinib is a targeted drug targeting ROS1 gene rearrangement. It is mainly used to treat adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This drug effectively prevents the growth and spread of tumor cells by inhibiting the kinase activity of ROS1. In recent years, with the in-depth research on non-small cell lung cancer, more and more targeted therapeutic drugs have been released. The launch of raptinib provides a new treatment option for ROS1-positive patients.

in the country, Ripotinib has been successfully launched and included in medical insurance. The implementation of this policy allows more patients in need of treatment to obtain the drug at a lower economic burden, improving their quality of life and prolonging their survival. According to the latest medical insurance policy, the scope of medical insurance reimbursement for Ripotinib is limited to adult patients diagnosed with ROS1-positive locally advanced or metastatic non-small cell lung cancer. In actual use, patients must undergo relevant examinations through the hospital to confirm whether there is ROS1 gene rearrangement in their tumor cells. Only eligible patients can enjoy medical insurance reimbursement.

The specifications of Ripotinib are40mg*120 tablets, and each box is priced at about more than 5,000 yuan. Specific prices may vary depending on the region, hospital and pharmacy, so patients are advised to consult their local hospital pharmacy for accurate price information when seeking medical treatment. In addition, due to the continuous updates of medical insurance policies, patients should also regularly pay attention to the relevant regulations of medical insurance to ensure that the treatment they need can be reimbursed smoothly.

For doctors, the application of repotinib provides a new treatment idea. Clinically, doctors can formulate personalized treatment plans based on the patient's specific situation and combined with his pathological test results. At the same time, due to some side effects that may occur during the treatment of repotinib, doctors need to pay close attention to the patient's physical response and adjust the medication regimen in a timely manner.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html